India, June 26 -- Johnson & Johnson (JNJ) announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress, offering deeper insight into the use of IMAAVY (nipocalimab-aahu) throughout the generalized myasthenia gravis (gMG) treatment journey.
New analyses from the Phase 3 Vivacity-MG3 study highlight the impact of IMAAVY in adults with anti-AChR+ or anti-MuSK+ antibody-positive gMG. These findings include patients early in their disease course, those with lower symptom burden, and participants who experienced common infections-conditions that often trigger disease exacerbations.
Johnson & Johnson will also present the innovative PETUNIA study design, which demonstrates how pregnancy outcomes data will be co...